Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers (NCT03035760) (2017)

Government Record · National Institute of Allergy and Infectious Diseases (NIAID) (lead sponsor) · May 12, 2017

National Institute of Allergy, 2017-05-12: Registry record for the NIAID multiple ascending dose oxfendazole study in 36 healthy adults, completed in 2018 with results posted.

NCT03035760 – Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers – Phase 1 – COMPLETED – Enrollment 36 – Start 2017-05-12 – Primary completion 2018-04-23 – Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Allergy, 2017-05-12: Registry record for the NIAID multiple ascending dose oxfendazole study in 36 healthy adults, completed in 2018 with results posted. Record field (registry entry) transcribed from the ClinicalTrials.gov API v2 record on 2026-11-19. Interventional phase 1; results posted; condition listed as 'Helminthic Infection'. Together with FBB-25 this documents that the human trial activity around this drug family is on oxfendazole, not fenbendazole. Registry entry; results posted. Counterpart of FBB-24.